How the changes in reimbursement status of Forxiga (dapagliflozin propanediol monohydrate) generics will affect market competition is gaining industry-wide attention. The generic versions, which had been introduced to the market in April last year, are facing price changes due to changes in their reimbursement status.

The premium pricing granted to first generics and Korea Innovative Pharmaceutical Companies ended on the 8th, and Ilsung Pharmaceuticals' reimbursement was suspended on the 9th.

Pharmaceutical companies are eyeing how these reimbursement changes will impact the generic market ahead of the market withdrawal of the original Forxiga.

According to industry source